France operates a national pharmacovigilance network coordinated by ANSM and supported by regional pharmacovigilance centres (CRPV).
Core official resources
- French Good Pharmacovigilance Practices — ANSM's national pharmacovigilance practice framework, updated in 2026.
- Declare an adverse effect — ANSM entry point for safety reporting.
- National reporting portal — reporting route for patients and healthcare professionals.
- ANSM public adverse-reaction data — public access to data derived from France's national pharmacovigilance database.
Practical use
France follows the EU pharmacovigilance framework but maintains a substantial national structure through the CRPV network and ANSM-specific good-practice material. The national guidance should therefore be considered alongside EU GVP rather than treated as a replacement for it.